1. Home
  2. VMD vs AKBA Comparison

VMD vs AKBA Comparison

Compare VMD & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VMD
  • AKBA
  • Stock Information
  • Founded
  • VMD 2006
  • AKBA 2007
  • Country
  • VMD United States
  • AKBA United States
  • Employees
  • VMD N/A
  • AKBA N/A
  • Industry
  • VMD
  • AKBA Biotechnology: Pharmaceutical Preparations
  • Sector
  • VMD
  • AKBA Health Care
  • Exchange
  • VMD Nasdaq
  • AKBA Nasdaq
  • Market Cap
  • VMD 294.7M
  • AKBA 336.2M
  • IPO Year
  • VMD N/A
  • AKBA 2014
  • Fundamental
  • Price
  • VMD $8.99
  • AKBA $1.92
  • Analyst Decision
  • VMD
  • AKBA Strong Buy
  • Analyst Count
  • VMD 0
  • AKBA 2
  • Target Price
  • VMD N/A
  • AKBA $5.75
  • AVG Volume (30 Days)
  • VMD 135.0K
  • AKBA 2.3M
  • Earning Date
  • VMD 11-06-2024
  • AKBA 11-07-2024
  • Dividend Yield
  • VMD N/A
  • AKBA N/A
  • EPS Growth
  • VMD 4.13
  • AKBA N/A
  • EPS
  • VMD 0.25
  • AKBA N/A
  • Revenue
  • VMD $214,301,000.00
  • AKBA $169,879,000.00
  • Revenue This Year
  • VMD $21.99
  • AKBA N/A
  • Revenue Next Year
  • VMD $11.87
  • AKBA $3.23
  • P/E Ratio
  • VMD $36.06
  • AKBA N/A
  • Revenue Growth
  • VMD 26.22
  • AKBA N/A
  • 52 Week Low
  • VMD $6.21
  • AKBA $0.80
  • 52 Week High
  • VMD $10.44
  • AKBA $2.48
  • Technical
  • Relative Strength Index (RSI)
  • VMD 59.94
  • AKBA 68.47
  • Support Level
  • VMD $8.95
  • AKBA $1.30
  • Resistance Level
  • VMD $9.81
  • AKBA $2.01
  • Average True Range (ATR)
  • VMD 0.29
  • AKBA 0.12
  • MACD
  • VMD -0.06
  • AKBA 0.04
  • Stochastic Oscillator
  • VMD 44.53
  • AKBA 78.52

About VMD Viemed Healthcare Inc.

Viemed Healthcare Inc is a provider of medical equipment and home therapy to patients with respiratory disease, oxygen problems, sleep apnea and PAP treatment. The company also provides services such as respiratory disease management, neuromuscular care, in-home sleep testing and sleep apnea treatment, oxygen therapy, respiratory equipment rentals, and healthcare staffing services. The company generates majority its revenue from medical equipment rental, sales and supply.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Share on Social Networks: